NeuBase Therapeutics (NBSE) 10-K2013 FY Annual report

Filed: 27 Dec 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accelerated, acceleration, Allegro, Almenoff, American, appeal, appurtenant, Arista, bachelor, background, bailey, Bausch, began, Biology, Branch, breaking, broadened, Buffalo, calendar, career, Central, chaired, Charter, Chasen, Chemist, colon, communicated, conceived, concomitant, contest, Council, creation, criteria, cum, deadline, Dean, device, Diabetic, discourage, Duke, EDT, educational, Electrochemistry, Eleven, embark, Energy, enjoy, entitled, esophageal, exacerbate, expert, faculty, fat, fellowship, felt, Florida, fractional, Furiex, Genie, GSK, half, Hearing, influential, Innovation, innovative, insufficient, integrin, invasive, IST, Japan, Jersey, Journal, Junior, Kobe, laude, literature, liver, Lomb, lung, mail, malone, Martin, masked, membership, monetize, monotherapy, Mt, myeloma, NanoVibronix, nasdaq, neck, notably, notified, NTOP, occasion, Occlusion, oncology, outlined, Paco, Palliative, pancreatic, paper, pharmacovigilance, pioneering, plaintiff, pm, podium, possessed, preferential, Presby, processed, Professor, proficiency, Proliferative, prolonged, prostate, radiotherapy, redemption, Regal, Reidhammer, remote, residency, Retinal, Retinopathy, revised, Riedhammer, settle, signal, Sinai, sinking, Sirion, Sjogren, slightly, split, Stanford, Stiefel, stomach, Summa, Surgical, Syndrome, tender, tenure, thereof, transition, Unamortized, understanding, Vein, Wall, Xcovery

Removed: absence, accompanied, acting, assuming, atrophy, avoiding, AVR, Barcelona, begin, bid, Bulletin, calling, capitalization, card, case, chance, chemoprotective, chemotherapeutic, circumvented, climate, collusion, combined, conclusion, Concurrently, dealing, decline, deficit, deterioration, disclosing, dispose, distance, doubt, economic, error, fatigue, faulty, feasibility, finalized, found, fraudulent, Incorporation, inducement, ineffective, intensive, IRS, lessen, liquidity, mistake, Motorola, NASD, newly, operational, OTC, OTCBB, outcome, override, penny, problem, prohibition, Project, publicized, QTDP, Qualifying, reduce, reimbursement, revaluation, revalued, semiconductor, separate, serving, Sigma, simple, Spain, spent, stability, stated, strike, structured, submission, succeed, suitability, Tegal, tolerate, toxic, utilized, vesting, VoIP, Zedge

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Ohr Pharmaceutical, Inc 10-k

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Annual Report of Ohr Pharmaceutical, Inc. (the“Company” ) on Form 10-K for the period ending September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the“Report” ), I, Irach Taraporewala , Chief Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 27, 2013

*/s/ Irach Taraporewala*
Name: Irach Taraporewala
Title: Chief Executive Officer